Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2009

View Archived Issues

Activity seen with eniluracil and 5-fluorouracil in hepatocellular carcinoma

Ferric carboxymaltose improves restless legs syndrome in double-blind study

Fate Therapeutics acquires intellectual property rights to osteogenic agents from UC

Morphotek and Synageva sign research collaboration for therapeutic monoclonal antibodies

Clopidogrel with aspirin reduces vascular event risk in atrial fibrillation patients

Study tests carotid plaque inflammation biomarker, atorvastatin effects

High response rates to RFB4(dsFv)-PE38 treatment in hairy cell leukemia

Actelion receives E.U. approval for pediatric dispersible formulation of Tracleer for PAH

Alcon initiates treatment in phase II trial of NovaBay's NVC-422 for viral conjunctivitis

Salvat launches antibiotic Cetraxal for otitis externa in the U.S.

Genentech reports results from phase III BRAVO study of Lucentis in branch RVO

GSK discontinues development of Kissei's SGLT2 inhibitor remogliflozin for diabetes

Sigma-Tau submits MAA to EMEA for antimalarial Eurartesim

Novartis enrolls first patient in phase III study of Sosei's NVA-237 for COPD

FDA approves Lilly's Alimta as maintenance therapy for NSCLC

Eisai to initiate U.S. clinical trial of Dacogen in pediatric AML

Initial tender offer for Cougar Biotechnology completed by Johnson & Johnson

Oxigene to acquire Symphony Vida and rights to OXi-4503 and Zybrestat for ophthalmology

BioCis Pharma reports results from phase IIa clinical trial of ProtoCure in dermatitis

Action Pharma discovers and patents novel melanocortin receptor ligands

Cellzome presents PI3Kgamma inhibitors for the treatment of immunological disorders

Polyamine analogues active against Enterocytozoon bieneusi in mouse model

Bar-Ilan University patent describes novel P2Y1 receptor agonists

Cubist initiates dosing in CONSERV-2 clinical trial of ecallantide for blood loss in surgery

CBP-501 initiates phase II clinical studies for non-small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...